US Senate Passes Eliminate Colorectal Cancer Act

Publication
Article
OncologyONCOLOGY Vol 16 No 10
Volume 16
Issue 10

The US Senate Health, Education, Labor, and Pensions Committee has passed the Eliminate Colorectal Cancer Act (S.710), legislation introduced by Sen. Jesse Helms (R-NC) and Sen. Edward M. Kennedy (D-Mass). The bill, with the companion

The US Senate Health, Education, Labor, and Pensions Committeehas passed the Eliminate Colorectal Cancer Act (S.710), legislation introducedby Sen. Jesse Helms (R-NC) and Sen. Edward M. Kennedy (D-Mass). The bill, withthe companion HR 1520 being mulled by the US House of Representatives, wouldrequire all private health insurance plans to cover colon cancer screeningaccording to scientific guidelines for patients age 50 and over and for othersat high risk of developing the disease.

In a statement, the American Cancer Society noted, "It isup to Congress to ensure that the barriers to life-saving colon cancerscreenings tests are removed. . . The bottom line is that this Act can helpprolong lives and prevent the pain and anguish cancer causes."

Recent Videos
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
Sotorasib plus panitumumab may offer improved survival compared with previously approved treatment options in KRAS G12C-mutated colorectal cancer.
Additional local, regional, or national policy may bolster access to screening for colorectal cancer, according to Aasma Shaukat, MD, MPH.
The mechanism of action for daraxonrasib inhibits effectors and signaling while forming a relatively unstable tri-complex with codon 12 mutations.
Almost all patients evaluable for efficacy reported a decrease in ctDNA when treated with daraxonrasib for RAS-mutant pancreatic ductal adenocarcinoma.
Additional progression-free survival data from the phase 3 BREAKWATER trial will be presented at future meetings.
As patients are nearing the end of life, different management strategies, such as opioids, may be needed to help mitigate pain or fatigue.
Kelley A. Rone, DNP, RN, AGNP-c, highlights the importance of having end-of-life discussions early in a patient’s cancer treatment course.
Related Content